 |
PDBsum entry 2uvz
|
|
|
|
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
|
|
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
|
|
|
|
|
|
|
|
|
Transferase/inhibitor
|
PDB id
|
|
|
|
2uvz
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
Contents |
 |
|
|
|
|
|
|
|
|
|
|
|
* Residue conservation analysis
|
|
|
|
|
PDB id:
|
 |
|
 |
| Name: |
 |
Transferase/inhibitor
|
 |
|
Title:
|
 |
Structure of pka-pkb chimera complexed with c-phenyl-c-(4-(9h-purin-6- yl)-phenyl)-methylamine
|
|
Structure:
|
 |
Camp-dependent protein kinase, alpha-catalytic subunit. Chain: a. Synonym: protein kinase a, pka c-alpha. Engineered: yes. Mutation: yes. Camp-dependent protein kinase inhibitor alpha. Chain: i. Fragment: residues 5-24. Synonym: pki, pki-alpha, muscle/brain isoform.
|
|
Source:
|
 |
Bos taurus. Bovine. Organism_taxid: 9913. Expressed in: escherichia coli. Expression_system_taxid: 562. Synthetic: yes. Homo sapiens. Human. Organism_taxid: 9606
|
|
Resolution:
|
 |
|
1.94Å
|
R-factor:
|
0.205
|
R-free:
|
0.245
|
|
|
Authors:
|
 |
T.G.Davies,A.Donald,T.Mchardy,M.G.Rowlands,L.J.Hunter,R.G.Boyle, G.W.Aherne,M.D.Garrett,I.Collins
|
|
Key ref:
|
 |
A.Donald
et al.
(2007).
Rapid evolution of 6-phenylpurine inhibitors of protein kinase B through structure-based design.
J Med Chem,
50,
2289-2292.
PubMed id:
|
 |
|
Date:
|
 |
|
15-Mar-07
|
Release date:
|
08-May-07
|
|
|
|
|
|
PROCHECK
|
|
|
|
|
Headers
|
 |
|
|
References
|
|
|
|
|
 |
|
|
 |
 |
 |
 |
Enzyme class:
|
 |
Chain A:
E.C.2.7.11.11
- cAMP-dependent protein kinase.
|
|
 |
 |
 |
 |
 |
Reaction:
|
 |
|
1.
|
L-seryl-[protein] + ATP = O-phospho-L-seryl-[protein] + ADP + H+
|
|
2.
|
L-threonyl-[protein] + ATP = O-phospho-L-threonyl-[protein] + ADP + H+
|
|
 |
 |
 |
 |
 |
L-seryl-[protein]
|
+
|
ATP
|
=
|
O-phospho-L-seryl-[protein]
|
+
|
ADP
|
+
|
H(+)
|
|
 |
 |
 |
 |
 |
L-threonyl-[protein]
|
+
|
ATP
|
=
|
O-phospho-L-threonyl-[protein]
|
+
|
ADP
|
+
|
H(+)
|
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
Molecule diagrams generated from .mol files obtained from the
KEGG ftp site
|
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
|
|
| |
|
|
| |
|
|
J Med Chem
50:2289-2292
(2007)
|
|
PubMed id:
|
|
|
|
|
| |
|
Rapid evolution of 6-phenylpurine inhibitors of protein kinase B through structure-based design.
|
|
A.Donald,
T.McHardy,
M.G.Rowlands,
L.J.Hunter,
T.G.Davies,
V.Berdini,
R.G.Boyle,
G.W.Aherne,
M.D.Garrett,
I.Collins.
|
|
|
|
| |
ABSTRACT
|
|
|
| |
|
6-phenylpurines were identified as novel, ATP-competitive inhibitors of protein
kinase B (PKB/Akt) from a fragment-based screen and were rapidly progressed to
potent compounds using iterative protein-ligand crystallography with a PKA-PKB
chimeric protein. An elaborated lead compound showed cell growth inhibition and
effects on cellular signaling pathways characteristic of PKB inhibition.
|
|
|
|
|
|
|
 |
 |
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
Literature references that cite this PDB file's key reference
|
|
 |
| |
PubMed id
|
 |
Reference
|
 |
|
|
|
 |
C.W.Murray,
and
T.L.Blundell
(2010).
Structural biology in fragment-based drug design.
|
| |
Curr Opin Struct Biol,
20,
497-507.
|
 |
|
|
|
|
 |
T.McHardy,
J.J.Caldwell,
K.M.Cheung,
L.J.Hunter,
K.Taylor,
M.Rowlands,
R.Ruddle,
A.Henley,
A.de Haven Brandon,
M.Valenti,
T.G.Davies,
L.Fazal,
L.Seavers,
F.I.Raynaud,
S.A.Eccles,
G.W.Aherne,
M.D.Garrett,
and
I.Collins
(2010).
Discovery of 4-amino-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamides as selective, orally active inhibitors of protein kinase B (Akt).
|
| |
J Med Chem,
53,
2239-2249.
|
 |
|
PDB codes:
|
 |
|
|
|
|
|
 |
X.Zhang,
A.C.Gibbs,
C.H.Reynolds,
M.B.Peters,
and
L.M.Westerhoff
(2010).
Quantum mechanical pairwise decomposition analysis of protein kinase B inhibitors: validating a new tool for guiding drug design.
|
| |
J Chem Inf Model,
50,
651-661.
|
 |
|
|
|
|
 |
A.G.Villaseñor,
R.Kondru,
H.Ho,
S.Wang,
E.Papp,
D.Shaw,
J.W.Barnett,
M.F.Browner,
and
A.Kuglstatter
(2009).
Structural insights for design of potent spleen tyrosine kinase inhibitors from crystallographic analysis of three inhibitor complexes.
|
| |
Chem Biol Drug Des,
73,
466-470.
|
 |
|
PDB codes:
|
 |
|
|
|
|
|
 |
E.Calvo,
V.Bolós,
and
E.Grande
(2009).
Multiple roles and therapeutic implications of Akt signaling in cancer.
|
| |
Onco Targets Ther,
2,
135-150.
|
 |
|
|
|
|
 |
G.E.de Kloe,
D.Bailey,
R.Leurs,
and
I.J.de Esch
(2009).
Transforming fragments into candidates: small becomes big in medicinal chemistry.
|
| |
Drug Discov Today,
14,
630-646.
|
 |
|
|
|
|
 |
R.L.van Montfort,
and
P.Workman
(2009).
Structure-based design of molecular cancer therapeutics.
|
| |
Trends Biotechnol,
27,
315-328.
|
 |
|
|
|
|
 |
J.Y.Lee,
M.H.Rhee,
and
J.Y.Cho
(2008).
Novel modulatory effects of SDZ 62-434 on inflammatory events in activated macrophage-like and monocytic cells.
|
| |
Naunyn Schmiedebergs Arch Pharmacol,
377,
111-124.
|
 |
|
 |
 |
|
The most recent references are shown first.
Citation data come partly from CiteXplore and partly
from an automated harvesting procedure. Note that this is likely to be
only a partial list as not all journals are covered by
either method. However, we are continually building up the citation data
so more and more references will be included with time.
Where a reference describes a PDB structure, the PDB
codes are
shown on the right.
|
');
}
}
 |
|